Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9890711 | 0.83 | HPGD (0.42) | SMN1; SMN2KMT2ANPC1POLBMEN1 | |
| SCHEMBL9890719 | 0.83 | KMT2A (0.49) | SMN1; SMN2KMT2ANPC1MEN1RAB9A | |
| SCHEMBL9890723 | 0.83 | LMNA (0.47) | SMN1; SMN2KMT2ANPC1MEN1RAB9A | |
| SCHEMBL2397254 | 0.79 | KMT2A (0.45) | SMN1; SMN2KMT2APOLBMEN1HPGD | |
| SCHEMBL16268539 | 0.78 | CA12 (0.56) | KMT2ANPC1RAB9AALDH1A1P2RX7 | |
| SCHEMBL9447453 | 0.78 | PTGS2 (0.54) | KMT2AMEN1HPGDALDH1A1GAA | |
| SCHEMBL3860837 | 0.76 | AKR1B1 (0.57) | KMT2ANPC1MEN1RAB9AKDM4E | |
| SCHEMBL29859740 | 0.76 | AKR1B1 (0.52) | SMN1; SMN2KMT2ANPC1MEN1RAB9A | |
| SCHEMBL9890710 | 0.76 | FFAR1 (0.43) | KMT2AMEN1HPGDALDH1A1KDM4E | |
| SCHEMBL8441394 | 0.75 | KMT2A (0.58) | SMN1; SMN2KMT2ANPC1MEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | SMN1; SMN2 2980/4885KMT2A 78/4885NPC1 1800/4885 |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | SMN1; SMN2 2980/4885KMT2A 78/4885NPC1 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.